Catalog No.	PA007525.m2a
Product Name	Anti-mouse NK1.1 Antibody (Clone: PK136) | PA007525.m2a
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	KLRB1C, CD161, Ly-59, NK-RP1, NK-1, Nk-1.2, Nkrp1c, Ly-55c
Clone	PK136.
Isotype	Mouse IgG2a kappa.
Source/Host	The anti-mouse NK1.1 monoclonal antibody (clone: PK136) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: PK136) specifically binds to mouse NK1.1.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse NK1.1 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The in vivo grade recombinant anti-mouse NK1.1 monoclonal antibody of clone PK136 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007525.m2a: In Vivo Grade Recombinant Anti-mouse NK1.1 Monoclonal Antibody (Clone: PK136), Mouse IgG2a Kappa

Recombinant mouse IgG2a Monoclonal Antibody.

References of Anti-mouse NK1.1 Monoclonal Antibody:

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi, R., et al. Nat Commun. 2016 Sep 21;7:12878. doi: 10.1038/ncomms12878. PMID: 27650575
Data were acquired flow cytometrically and is representative of three separate experiments with MFI comparison of PE-labelled constructs on NK cells (viable, NK1.1+, CD3?, CD19?). … NK cells were defined as viable, NK1.1+CD3?CD19?. … For NK cell depletion, mice were treated with anti-NK1.1 antibody (clone PK136) or mouse IgG isotype control (both from BioXcell) at 500 ?g day ?2, 250 ?g day ?1 and 250 ?g weekly for the duration of the experiment. … Data representative of 5 mice per group for both NK1.1 depleted and NKG2D deficient mice. (f) LLC tumour growth in C57BL/6Rag1?/? mice. …Increased efficacy of OMCP-mutIL-2 immunotherapy disappears in NKG2D?/? or NK1.1 depleted mice.
Tags: anti-mouse NK1.1 PK136; anti-mouse NK1.1 PK136 antibody

NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.
Ludigs, K., et al. Nat Commun. 2016 Feb 10;7:10554. doi: 10.1038/ncomms10554. PMID: 26861112
(b) H2-K and H2-D expression, depicted as mean fluorescence intensity (MFI), was analysed by flow cytometry on splenic CD4+ and CD8+ T cells (CD3+CD4+ and CD3+ CD8+, respectively), NK cells (NK1.1+CD3 ?), B cells (CD19+) and DCs (CD11c high) from Nlrc5 fl/fl, Nlrc5 ?/? and B2m ?/? mice. … In some mice, NK cells were depleted by intraperitoneal injection of 200 ?g of ?-NK1.1 antibody (PK-136, purchased from BioXcell) 1?2 days before cell transfer. … NK cells were isolated using the NK-cell-negative selection kit from StemCell Technologies (Grenoble, France), according to the manufacturer’s recommendations. … NK1.1 (PK-136, 1:100), NKp46 (29A1.4, 1:100), Qa2 (69H1-9-9, 1:200), Rae1? (RD-41, 1:75) (all from eBioscience), H2-L d (28-14-8, 1:200), Ly49H (3D10, 1:100) and Ly49C/I (5E6, 1:100; from BioLegend). … In some mice, NK cells were depleted as described above.
Tags: anti-mouse NK1.1 PK136 in animal model; anti-mouse NK1.1 PK136 antibody in animal model

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo, Z., et al. PLoS One. 2014 Feb 27;9(2):e89350. doi: 10.1371/journal.pone.0089350. PMID: 24586709
Therapeutic anti-OX40 (Clone OX-86; Catalog#:BE0031), anti-PD-1 (Clone RMT3-23; Catalog#BE0115), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036) and control rat IgG2a mAb (Clone 2A3; Catalog#:BE0089) were purchased from BioXcell (West Lebanon, NH). … For depletion of lymphocyte subsets, mice were injected i.p. with 500 ?g of mAb against CD8, CD4, or NK1.1, 1 day before and two days after tumor challenge, followed by injection of 200 ?g every 5 days throughout the experiment. … Lymphocyte subset depletion experiments demonstrated that tumor protection by anti-PD-1/OX40 mAbs was dependent on the CD4+ and CD8+ T cells as removal of CD4+ or CD8+ T cells but not NK cells completely abrogated the antitumor effect conferred by anti-PD-1/OX40 mAb treatment. … Mice (5 mice per group) injected i.p. with 1×106 ID8 cells 10 day earlier were injected thrice at 4 days interval with 200 ?g of control, single or combined anti-PD-1/OX40 mAb. Three or seven days later, peritoneal lavages from treated mice were analyzed by flow cytometry for the composition of various immune subsets. … The percentages of CD4+FoxP3? T cells, CD8+ T cells, CD4+FoxP3+ Treg and CD11b+GR-1+ MDSC in CD45+ peritoneal immune cells are shown in A, B, C and D respectively with each dot representing data from each mouse.
Tags: anti-mouse NK1.1 PK136 antibody in vivo; anti-mouse NK1.1 PK136 in mouse tumor model

Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.
Walsh, K. B., et al. J Virol. 2014 Jun;88(11):6281-93. doi: 10.1128/JVI.00464-14. PMID: 24672024
For cell depletion experiments, 250 ?g of anti-NK1.1 (PK136; Bioxcell) and/or 500 ?g of anti-CD8 (53-6.72; Bioxcell) antibodies were administered i.p. to mice 1 day before and 1 day after infection. … Isolated cells were stained with antibodies raised against murine CD11b (M1/70), CD11c (HL3), Ly6C (HK1.4), Ly6G (1A8), F480 (BM8), NK1.1 (PK136), CD3e (145-2C11), CD4 (L3T4), CD8a (53-6.7), CD90.2 (53-2.1), B220 (RA3-6B2), CD103 (M290), CD69 (HI.2F3), CD44 (IM7), CD40 (MH40-3), CD80 (16-10A1), CD86 (GL1), PD-L1 (MIH5), H-2Kb (AF6-88.5), and I-A/I-E (M5/114.15.2). … Cytokine production by NK cells and CD8+ T cells within the lung on day 5 after PVM infection was determined by 5 h of incubation of single-cell suspensions in culture medium (RPMI with 10% fetal bovine serum [FBS], 2 mM l-glutamine, and 100 U [each] of penicillin-streptomycin) with 4 ?g/ml brefeldin A (Sigma, St. Louis, MO, USA) in the absence of exogenous stimulation. …NK cells and CD8+ T cells were stained for surface antigen (NK1.1+ CD3? and CD8+ CD90.2+, respectively), fixed, permeabilized with 2% saponin, and then stained for intracellular proteins with fluorescently labeled antibodies specific for murine IFN-? (XMG1.2) and TNF-? (MP6-XT22). … In flow cytometric analysis, lung infiltrates of mice given RP-002 showed significantly fewer CD8+ T cells and NK cells than vehicle on day 5 postinfection.
Tags: function of anti-mouse NK1.1 PK136; function of anti-mouse NK1.1 PK136 mAb

Therapeutic efficacy of bifunctional siRNA combining TGF-?1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier, J., et al. Cancer Res. 2013 Mar 15;73(6):1709-20. doi: 10.1158/0008-5472.CAN-11-3850. PMID: 23338611
Where indicated, CD8? T cells or NK cells were depleted one day before RNA treatment with 500 ?g of anti-CD8 monoclonal antibody (mAb; clone YTS 169.4) or anti-NK1.1 mAb (clone PK136; BioXCell). … Depletion efficacy was assessed by fluorescence-activated cell sorting (FACS) analysis of peripheral blood and was more than 98% after 24 hours. … Therapeutic efficacy was dependent on CD8? T cells, whereas natural killer cells were dispensable. … Intravenous injection of ppp-TGF-? reduced systemic and tumor-associated TGF-? levels. … In addition, it induced high levels of type I IFN and CXCL10 in serum and tumor tissue, systemic immune cell activation, and profound tumor cell apoptosis in vivo.
Tags: anti-NK1.1 (PK136) monoclonal antibody; mouse NK1.1 antibody (clone PK136)

Macrophage and T cell produced IL-10 promotes viral chronicity.
Richter, K., et al. PLoS Pathog. 2013;9(11):e1003735. doi: 10.1371/journal.ppat.1003735. PMID: 24244162
Depletion of NK-like cells was performed by i.p. administration of 300 ?g ?NK1.1 (PK136, BioXCell) on days -3 and -1 (depletion efficacy of 96% while the percentage of CD3+ cells was not affected). … NK cells constituted 0.96±0.23% of the splenocytes on day 2 and 1.81±0.13% on day 5 post infection while NKT cells accounted for 0.11±0.05% on day 2 and 0.2±0.03% on day 5. … Depletion of neutrophils, CD4+ or CD8+ T cells, CD25+ T cells and B cells did not lead to a decrease in the overall IL-10 mRNA levels. …Unexpectedly, depletion of NK-like cells did not result in overall decreased IL-10 mRNA levels despite the high IL-10 mRNA expression level in purified cells. … NK cells were isolated from splenocytes on day 7 after i.p. infection with 5×104 pfu MCMV Smith by magnetic negative selection of CD3+ and CD19+ cells and subsequent FACS sorting of CD3? NK1.1+ cells.
Tags: anti-mouse NK1.1 PK136 in animal model; anti-mouse NK1.1 PK136 antibody in animal model

For more references about Anti-mouse NK1.1 Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

In Vivo Grade Recombinant Anti-mouse NK1.1 Monoclonal Antibody (Clone: PK136), Mouse IgG2a Kappa from: In Vivo Grade Recombinant Anti-mouse NK1.1 Monoclonal Antibody (Clone: PK136), Mouse IgG2a Kappa: PA007525.m2a Syd Labs

No more offers for this product!